William Blair & Company
RPRX icon

William Blair & Company’s Royalty Pharma RPRX Stock Holding History

William Blair & Company’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Sell
4,252
-1,614
-28% -$84K ﹤0.01% 1509
2026
Q1 		$281K Buy
+5,866
New +$257K ﹤0.01% 1360
2025
Q4 		– Sell
-7,263
Closed -$256K – 1932
2025
Q3 		$256K Buy
7,263
+462
+7% +$16.7K ﹤0.01% 1363
2025
Q2 		$245K Hold
6,801
– – ﹤0.01% 1341
2025
Q1 		$212K Buy
+6,801
New +$216K ﹤0.01% 1385
2024
Q3 		– Sell
-8,420
Closed -$222K – 1864
2024
Q2 		$222K Buy
+8,420
New +$233K ﹤0.01% 1372

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair & Company's RPRX Position: Q2 2026 in Review

William Blair & Company reduced its Royalty Pharma (RPRX) stake by 28% in Q2 2026, selling an estimated $84K and leaving 4,252 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #1509.

William Blair & Company first reported a position in RPRX in Q2 2024 and has held it in 6 quarters since. The position peaked at $281K in Q1 2026. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • William Blair & Company held 4,252 shares of Royalty Pharma worth $238K as of Q2 2026.
  • William Blair & Company sold 1,614 Royalty Pharma shares in Q2 2026, an estimated $84K.
  • Royalty Pharma made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1509 holding.
  • William Blair & Company first reported a position in Royalty Pharma in Q2 2024 and has held it in 6 quarters since.
  • William Blair & Company's Royalty Pharma position peaked at $281K in Q1 2026.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.